Physician
Oncology
Dr. H I. Robins, MD
|
|
Give Review
Doctor H I. Robins, MD is an expert in the field of Oncology. He researched medicine at Boston University School of Medicine. Boston University School of Medicine has a rank of 30 in research and a 52 in primary care He over the years received 1 awards: "Regional Top Doctor". Doctor H I. Robins, MD is also a published doctor. He has 56 publication published. The most recent publication is: Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
- Veliparib in combination with whole Brain radiation therapy in patients with Brain metastases: results of a phase 1 study.
- Strategies to prevent Brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.
- Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial Tumors.
- "TRIMing" the Patient Population to Increase the Benefit of mTOR Inhibition.
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
- In regard to sperduto et Al.
- Pseudoprogression after glioma therapy: a comprehensive review.
- RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients.
- Histological predictors of outcome in ependymoma are dependent on anatomic site within the central Nervous system.
- A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer ...
- Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept.
- Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase.
- Myeloid Biomarkers Associated with Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept.
- International retrospective study of over 1000 adults with anaplastic oligodendroglial Tumors.
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study.
- Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy.
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium St...
- ACR Appropriateness Criteria: single Brain metastasis.
- Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
- Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
- Therapeutic advances in malignant glioma: current status and future prospects.
- More on reports of esophageal Cancer with oral bisphosphonate use.
- EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
- Prospective evaluation of quality of life and neurocognitive effects in patients with multiple Brain metastases receiving whole-Brain radiotherapy with or without thal...
- A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple Brain metastases (RTOG 0118).
- Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
- Primary disease resection in metastatic breast Cancer improves survival.
- Therapeutic advances for glioblastoma multiforme: current status and future prospects.
- Therapeutic advances in the treatment of Brain metastases.
- Temozolomide as prophylaxis for Brain metastasis in non-small cell lung cancer.
- Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
- Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain ...
- Pathophysiology and management of fever revisited.
- Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.
- Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
- Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
- Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Tr...
- O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic Gliomas.
- Combined modality treatment for central Nervous system malignancies.
- A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
- Trastuzumab for breast Cancer-related carcinomatous meningitis.
- A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North America...
- A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
- Whole body hyperthermia: simple complexities.
- Phase I trial of intravenous thymidine and carboplatin in patients with advanced Cancer.
- Role of tumor necrosis factor alpha in hyperthermia-induced apoptosis of human leukemia cells.
- Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.
- Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity.
- Heat shock protein antibodies in sarcoma patients undergoing 41.8 degrees C whole body hyperthermia.
- Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).
- Pentoxifylline treatment of radiation mastitis.
- Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.
- Radiotherapy and chemotherapy in high-risk breast Cancer.
- Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in Cancer patients.
Schools
Boston University School Of Medicine
University Wisc Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Wisconsin -
Boston University School of Medicine
Hospital
-
University of Wisconsin Hospital and Clinics
Drug Facts
| NPI NUMBER | 1053372953 | |
| NPPES Provider LastName | ROBINS | |
| NPPES Provider FirstName | H | |
| NPPES Provider ZIPCode | 53792 | |
| NPPES Provider State | WI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 328.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 4.57 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1053372953 |
| Last Name Of The Provider | ROBINS |
| First Name Of The Provider | H |
| View All |
Similar Doctors
|
|
Dr. Mark E. Burkard, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles H. Diggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amye J. Tevaarwerk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dustin A. Deming, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sam J. Lubner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ticiana B. Leal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alissa A. Weber, MD
This Doctor is OpenDoctor Recommended.
|